Clinical Trial Update: Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added) [Phase 3]

View source ↗

Summary

This is a Phase 3 CHARM Added trial evaluating candesartan cilexetil in patients with heart failure already on ACE inhibitors; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Atacand (candesartan)

Snippet

Sponsor: AstraZeneca | Conditions: Congestive Heart Failure | Phase 3 | Status: COMPLETED